论文部分内容阅读
近年来高渗氯化钠(NaCI)的临床应用有很多研究进展,在临床应用中受到高度重视,在纠正因限钠、利尿治疗使血浆钠下降,腹水消失时间延长的肝硬化腹水患者、低渗性脑病,心脏与神经疾病及抗体克作用中发挥着巨大作用,现将应用研究进展综述如下.1 在肝硬化腹水患者中的应用肝硬化腹水患者多给予限钠、利尿、导泻或发汗治疗,因忽视钠的补充,结果使血浆钠下降,导致电解质紊乱,腹水消失时间延长,利尿剂作用减弱或消失及诱发低渗性脑病等,在应用利尿剂时如何预防与纠正血浆低钠问题至今未引起广泛重视.最近有人通过临床研究与观察、发现肝硬化腹水限钠、利尿治疗的患者中92.4%的患者血浆钠<135mmol/L,如继续限钠、利尿治疗全部患者均可发生低钠血症.如单纯使用氨苯喋啶时尿钠排出增加53mmol/d,单用双氢克尿噻尿钠排出105mmol/d,两者合用时则尿钠排出增至168mmol/
In recent years, there are many clinical applications of hypertonic sodium chloride (NaCI), which have received great attention in clinical application. In correcting cirrhosis patients with ascites due to limited sodium and diuretic treatment, Osmotic encephalopathy, heart and nerve disease and antibody g plays a huge role in the application of progress are summarized below .1 in patients with cirrhosis and ascites in patients with cirrhosis and ascites were given more limited sodium, diuretic, cathartic or perspiration Treatment, due to neglect of sodium supplementation, resulting in decreased plasma sodium, resulting in electrolyte imbalance, prolonged ascites disappear, diuretic effect weakened or disappeared and induced hypotonic encephalopathy, how to prevent and correct plasma sodium in the application of diuretics So far it has not attracted much attention.Recently through clinical research and observation, found that patients with cirrhosis of the ascites limit sodium, diuretic treatment of 92.4% of patients with plasma sodium <135mmol / L, as continued sodium restriction, diuretic treatment can occur in all patients with low Sodium hyperlipidemia, such as simple use of methotrexate urine sodium excretion increased 53mmol / d, single hydrochlorothiazide sodium excretion 105mmol / d, the combination of both urine sodium excretion To 168mmol /